Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Alto Neuroscience highlighted a new Nature Medicine publication showing that pramipexole significantly reduces anhedonia in patients with mood disorders. The independent, placebo-controlled trial by Lund University found a significant effect on the primary endpoint (Hedges’ g=0.62, p=0.006), with benefits sustained through six months of open-label treatment. These findings reinforce the scientific basis for Alto’s lead asset ALTO-207, a combination of pramipexole and ondansetron designed to mitigate the nausea that limits pramipexole use.
Key figures
- Drug Name
- ALTO-207
- Phase Of Trial
- Phase 2b
- Nausea rate
- 60%
- Pramipexole p value
- 0.006
- Pramipexole effect size
- 0.62
- Mdd subgroup effect size
- 0.99
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.